Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures

Purpose: The acute, subacute, and chronic effects of vigabatrin (VGB) were studied in patients with refractory complex partial seizures. VGB increases human brain gamma-aminobutyric acid (GABA) and the related metabolites, ho mocarnosine and 2-pyrrolidinone. Methods: In vivo measurements of GABA and homocarnosine were made of a 14-c c volume in the occipital cortex by using H-1 spectroscopy with a 2.1-Tesla magnetic resonance spectrometer and an 8-cm surface coil. Six patients (th ree women) were studied serially during the initiation and maintenance of V GB as adjunct therapy. Results: The first, 3 g dose of VGB increased brain GABA by 2.0 mu mol/g wi thin 81 min of oral administration. After 2 h, median edited GABA remained essentially the same for 2 days. The response to the second, 3-g dose of VG B given at 48 h was considerably less than that to the first dose, with a m edian increase of 0.5 mu mol/g within 72 min. After 2-3 months, rechallengi ng patients taking 1.5-g VGB twice daily with 6 g increased GABA by 0.4 mu mol/g within 87 min. Homocarnosine increased more gradually than GABA to ab ove-normal levels after a week of VGB therapy. Conclusions: VGB promptly elevates brain GABA and presumably offers partial protection against further seizures within hours of the first oral dose. O nce-a-day dosing is sufficient to increase GABA. Patients may be expected t o experience the effects of increased homocarnosine within 1 week.